Literature DB >> 28068169

Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective.

Christina Fotopoulou1, Jalid Sehouli1, Giovanni Aletti1, Philipp Harter1, Sven Mahner1, Denis Querleu1, Luis Chiva1, Hani Gabra1, Nicoletta Colombo1, Andreas du Bois1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28068169     DOI： 10.1200/JCO.2016.71.0723

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.

Authors:  Eleonora Ghisoni; Dionyssios Katsaros; Furio Maggiorotto; Massimo Aglietta; Marco Vaira; Michele De Simone; Gloria Mittica; Gaia Giannone; Manuela Robella; Sofia Genta; Fabiola Lucchino; Francesco Marocco; Fulvio Borella; Giorgio Valabrega; Riccardo Ponzone
Journal:  J Ovarian Res       Date:  2018-05-30       Impact factor: 4.234

2.  Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patents with stage IIIC-IV ovarian cancer.

Authors:  Roberto Tozzi; Jvan Casarin; Ahmet Baysal; Gaetano Valenti; Yakup Kilic; Hooman Soleymani Majd; Matteo Morotti
Journal:  J Gynecol Oncol       Date:  2018-11-30       Impact factor: 4.401

3.  Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome.

Authors:  Marcia Hall; Konstantinos Savvatis; Katherine Nixon; Maria Kyrgiou; Kuhan Hariharan; Malcolm Padwick; Owen Owens; Paula Cunnea; Jeremy Campbell; Alan Farthing; Richard Stumpfle; Ignacio Vazquez; Neale Watson; Jonathan Krell; Hani Gabra; Gordon Rustin; Christina Fotopoulou
Journal:  Ann Surg Oncol       Date:  2019-06-26       Impact factor: 5.344

4.  Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer.

Authors:  Blair McNamara; Rosa Guerra; Jennifer Qin; Amaranta D Craig; Lee-May Chen; Madhulika G Varma; Jocelyn S Chapman
Journal:  Gynecol Oncol Rep       Date:  2021-09-25

5.  Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin.

Authors:  Yin Tao; Xue-Ting Tang; Xing Li; An-Shan Wu; Hou-Shen Zhou; Cheng-Fang Zhou
Journal:  Front Med (Lausanne)       Date:  2022-03-09

Review 6.  Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research.

Authors:  James Clark; Christina Fotopoulou; Paula Cunnea; Jonathan Krell
Journal:  Front Oncol       Date:  2022-03-25       Impact factor: 6.244

7.  How to predict treatment failure in frail patients with advanced epithelial ovarian cancer: strategies to personalize surgical effort.

Authors:  Christina Fotopoulou
Journal:  J Gynecol Oncol       Date:  2019-11-01       Impact factor: 4.401

8.  Feature Selection is Critical for 2-Year Prognosis in Advanced Stage High Grade Serous Ovarian Cancer by Using Machine Learning.

Authors:  Alexandros Laios; Angeliki Katsenou; Yong Sheng Tan; Racheal Johnson; Mohamed Otify; Angelika Kaufmann; Sarika Munot; Amudha Thangavelu; Richard Hutson; Tim Broadhead; Georgios Theophilou; David Nugent; Diederick De Jong
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.